A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Cancer
Melanoma
Metastatic Melanoma
Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer
Solid Tumors
Esophageal Squamous Cell Carcinoma

Results
Download

Study results

LPS NP40435 Final Results February 2025 English (PDF, 0.8 MB)

LPS NP40435 Final Results February 2025 Danish (PDF, 0.8 MB)

LPS NP40435 Final Results February 2025 French.pdf (PDF, 0.8 MB)

LPS NP40435 Final Results February 2025 Korean (PDF, 0.7 MB)

LPS NP40435 Final Results February 2025 Spanish (PDF, 0.5 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

Study results

LPS NP40435 Final Results February 2025 English (PDF, 0.8 MB)

LPS NP40435 Final Results February 2025 Danish (PDF, 0.8 MB)

LPS NP40435 Final Results February 2025 French.pdf (PDF, 0.8 MB)

LPS NP40435 Final Results February 2025 Korean (PDF, 0.7 MB)

LPS NP40435 Final Results February 2025 Spanish (PDF, 0.5 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

External Site

Directly contact Roche for questions

Contact the hospital directly

You are about to leave ForPatients

Thank you

Request a call back

Find participating medical centers and current study status in each of them

A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors

For the latest version of this information please go to www.forpatients.roche.com